{"filings":[{"id":1702676,"accession_number":"0001213900-26-078937","cik":1415397,"company_name":"Raphael Pharmaceutical Inc.","ticker":"RAPH","form_type":"8-K","filed_at":"2026-07-17T13:20:50+00:00","items":["5.02"],"status":"ready","headline":"Chairman and CFO resign; Uri Tadelis appointed as new CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ajay Kumar Dhadha resigned as Chairman and Director effective June 30, 2026.","Guy Ofir resigned as CFO, General Counsel, and Director effective July 16, 2026.","Both resignations were not due to any disagreement with the company.","Uri Tadelis appointed as CFO effective July 16, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28250000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103800,"accession_number":"0001213900-26-033507","cik":1415397,"company_name":"Raphael Pharmaceutical Inc.","ticker":"RAPH","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Yehuda Eliya term expires, leaves Raphael board effective Dec 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Yehuda Eliya's board term expired Dec 31, 2025; ceased serving as director.","Departure not related to any disagreement with company operations, policies, or practices.","No replacement director announced as of filing date March 24, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":28250000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136623,"accession_number":"0001213900-25-074293","cik":1415397,"company_name":"Raphael Pharmaceutical Inc.","ticker":"RAPH","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Raphael Pharma board member resigns; Zvi Laufer Laor appointed as director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Igal Louria Hayon resigned from Board effective Aug 1, 2025; no disagreement; remains CTO.","On Aug 7, 2025, Board appointed Zvi Laufer Laor (age 73, lawyer) to fill vacancy.","Board determined Mr. Laufer qualified and independent under relevant securities laws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":28250000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136622,"accession_number":"0001213900-25-073909","cik":1415397,"company_name":"Raphael Pharmaceutical Inc.","ticker":"RAPH","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Raphael Pharmaceutical ready to launch RaphaWell RA supplement in US after clinical trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RaphaWell is a 100% natural, plant-based dietary supplement for rheumatoid arthritis symptom management.","Completed proof-of-concept clinical trial under IRB approval; pain levels reduced from 75% negative to 50% at week 8.","Morning stiffness improved from 75% participants at baseline to 41.67% at week 8.","Company intends to engage a US manufacturer to scale production; product to be sold as standalone supplement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28250000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172511,"accession_number":"0001213900-25-003401","cik":1415397,"company_name":"Raphael Pharmaceutical Inc.","ticker":"RAPH","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Raphael Pharmaceuticals appoints Ajay Kumar Dhadha as Director and Chairman, replacing Shlomo Pilo","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded by one seat; Ajay Kumar Dhadha appointed Director and Chairman effective January 8, 2025.","Dhadha, age 79, is a diamond dealer, founder/CEO of Shanti Gems (1982) Ltd., and Israel Diamond Exchange member.","No arrangement, transaction, or reportable relationship exists between Dhadha and the company under Item 404(a).","Board concluded Dhadha is qualified and independent; standard indemnification agreement to be entered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":28250000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189506,"accession_number":"0001213900-24-113467","cik":1415397,"company_name":"Raphael Pharmaceutical Inc.","ticker":"RAPH","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Raphael Pharma reports positive proof-of-concept study of cannabinoid formula in RA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DAS28 score reduced by 19.2%, moving from high to moderate disease activity in 12 patients.","Participants in remission increased from 0% at baseline to 16.67% at week 8.","Pain levels dropped from 75% reporting negative result to 50%; morning stiffness from 75% to 41.67%.","91.7% of participants would recommend Raphael's Formula to others with RA; 83.3% willing to continue use.","Blood biomarkers showed no statistically significant changes, but overall symptom management improved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28250000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206009,"accession_number":"0001213900-24-077706","cik":1415397,"company_name":"Raphael Pharmaceutical Inc.","ticker":"RAPH","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Raphael Pharmaceutical dismisses auditor Weinstein International, appoints Elkana Amitai CPA on short-term basis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Weinstein International CPA dismissed as independent auditor effective September 5, 2024.","Prior auditor's reports for FY 2022 and 2023 contained a going concern qualification.","New auditor Elkana Amitai CPA engaged for quarter ending September 30, 2024, on a short-term basis.","No disagreements or reportable events occurred during the past two fiscal years and interim period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28250000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223022,"accession_number":"0001213900-24-056191","cik":1415397,"company_name":"Raphael Pharmaceutical Inc.","ticker":"RAPH","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Raphael Pharmaceutical increases authorized common shares to 50M (from 21M)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 21,020,560 to 50,000,000 effective June 26, 2024.","Board approved the increase on May 9, 2024; majority shareholders approved on May 22, 2024.","Company filed Amended and Restated Articles of Incorporation with Nevada Secretary of State."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28250000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223021,"accession_number":"0001213900-24-039106","cik":1415397,"company_name":"Raphael Pharmaceutical Inc.","ticker":"RAPH","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Raphael Pharma launches US proof-of-concept CBG trial for rheumatoid arthritis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proof-of-concept clinical trial begun in US for Cannabigerol (CBG) in active Rheumatoid Arthritis patients.","Engaged MindMate/Citruslabs to oversee trial; estimated timeline 6 months from first participant recruitment.","Trial leverages pre-clinical experiments conducted at Rambam Health Care Campus, Israel.","No financial guidance or material financial impact disclosed in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28250000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315636,"accession_number":"0001213900-23-023667","cik":1415397,"company_name":"Raphael Pharmaceutical Inc.","ticker":"RAPH","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Israeli Ministry of Health approves Raphael Pharma's Phase IIa COVID-19 trial for cannabis-based drug","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Israeli Ministry of Health approved Raphael Pharmaceutical's application to commence a Phase IIa clinical trial in COVID-19 patients.","The trial protocol was approved by the Helsinki Committee at Rambam Hospital on December 8, 2022.","The trial involves a cannabis-based drug aimed at mitigating deterioration in COVID-19 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28250000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315635,"accession_number":"0001213900-23-005219","cik":1415397,"company_name":"Raphael Pharmaceutical Inc.","ticker":"RAPH","form_type":"8-K/A","filed_at":"2023-01-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Raphael Pharma corrects CTO deal: $9k/month, 999k warrants at $0.01, royalty share","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Service agreement with CTO Dr. Igal Louria Hayon corrected, monthly fee $9,000 through Dec 31, 2022.","Issuance of 999,000 warrants at $0.01 per share, expiring July 5, 2024.","Additional 350,000 warrants at $0.01 if company initiates cannabis clinical trial or new cannabis research.","Royalty payments: 15% of net royalties from medical cannabis CBD oil for COVID-19 and for rheumatoid arthritis.","Term through Dec 31, 2023; termination requires 120 days notice and fee equal to remaining monthly fees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28250000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333972,"accession_number":"0001213900-22-065828","cik":1415397,"company_name":"Raphael Pharmaceutical Inc.","ticker":"RAPH","form_type":"8-K","filed_at":"2022-10-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Raphael Pharmaceutical accepted for OTCQB up-list, to trade under 'RAPH'","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Application submitted September 1, 2022; notified of acceptance on October 7, 2022.","Will trade on OTCQB under ticker symbol 'RAPH' after trading approval from OTC Markets.","Company has paid required fees and increased financial transparency to meet OTCQB standards.","Management believes the up-list better positions the company for a greater growth trajectory."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":28250000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351408,"accession_number":"0001213900-22-037819","cik":1415397,"company_name":"Raphael Pharmaceutical Inc.","ticker":"RAPH","form_type":"8-K","filed_at":"2022-07-07T23:59:59+00:00","items":["4.01","5.02","9.01"],"status":"ready","headline":"Raphael Pharma dismisses Deloitte auditor, Chairman Press resigns; new exec comp agreements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed Brightman Almagor Zohar (Deloitte) as auditor; appointed Weinstein International as new independent auditor.","Chairman Prof. Joseph Press resigned from board effective June 30, 2022; consulting fee $1,000/meeting, 280k shares, 105k warrants at $1.12.","CEO Shlomo Pilo (Sheffa Enterprises) gets new management agreement: $10k/mo (2022) then $20k/mo, 1M warrants at $1.12, expires Dec 2024.","CFO Guy Ofir gets operations agreement: $6k/mo (2022) then $12k/mo, 1M restricted shares, 1M warrants at $1.00, expires Dec 2024.","CTO Dr. Igal Louria Hayon: $9k/mo (2022) then $12k/mo, 990k warrants at $0.01, plus 15% of royalties from cannabis COVID and RA indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28250000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}